Pediatric Anesthesiology
15 cases on repeated-anesthesia neurotoxicity and remimazolam adoption, difficult-airway and premedication technique, post-tonsillectomy analgesia and PONV prophylaxis, regional-block dosing ceilings, perioperative stimulant and cardiac-risk management, and neonatal and infant dosing — choose a case below to open its full multi-voice debate.
A single patient facing a fourth general anesthetic before his third birthday. The dispute isn't whether the reassuring human trials apply to him — everyone agrees they don't — it's what a clinician owes a family when the FDA's own warning outran the data it was built on.
A single patient scheduled for a short MRI under sedation. The disagreement isn't about whether remimazolam works — the hemodynamic numbers are real — it's about what 'reversible' should mean when the reversal agent carries its own re-sedation risk in a drug this new to pediatrics.
A single patient with an anticipated difficult airway. The disagreement isn't about whether spontaneous ventilation matters here — everyone agrees it does — it's about which induction path actually protects it once the mask goes on.
A single patient whose real barrier to a calm induction isn't the anesthetic plan, it's the ninety seconds beforehand. The disagreement is about which premedication actually gets her calmly to the mask, not which one looks better on paper.
A single patient with two prior thrashing emergences behind him. The disagreement isn't whether dexmedetomidine works for this — it does — it's whether giving it prophylactically to every child at his risk level is a good trade against the sedation it adds to recovery.
A single patient going home after tonsillectomy. The disagreement isn't about the codeine warning — nobody's arguing for that — it's about whether the NSAID everyone reaches for next is actually as safe here as it's assumed to be.
A single patient about to receive a drug nearly every tonsillectomy gets. The disagreement isn't whether dexamethasone reduces vomiting — it clearly does — it's whether the dose being reached for by habit is actually the dose the evidence supports.
A single patient needing thirty motionless minutes for an MRI. The disagreement isn't nostalgic for chloral hydrate — nobody wants it back — it's about which of its modern replacements actually fits a child with his specific risk profile.
A single patient getting a single-shot caudal for outpatient surgery. The disagreement is about which adjunct actually buys the extra hours of coverage this family needs, and what each one costs to get there.
A single patient whose regional block dose sits between two different published safety ceilings. The disagreement isn't about local anesthetic systemic toxicity in the abstract — everyone respects it — it's about which of two real, competing dosing guidelines should set today's actual number.
A single patient on chronic stimulant therapy facing routine surgery. The disagreement isn't about whether stimulants and anesthesia can coexist safely — they usually do — it's about whether 'usually' is good enough for the specific cardiovascular question this case actually raises.
A single patient needing antiemetic prophylaxis with a family cardiac history nobody had flagged before today. The disagreement isn't whether ondansetron's QTc warning is real — it is — it's whether it actually applies at the pediatric dose being considered here.
A single patient needing emergency rapid-sequence induction with a family history that makes one specific drug the very drug most guidelines warn hardest against. The disagreement is about whether the emergency itself outweighs a warning that exists precisely for emergencies like this one.
A single patient whose two most relevant numbers, his actual weight and his ideal weight, point toward very different drug doses. The disagreement is about which one should actually govern, and for which drugs specifically — not a single answer that applies uniformly across the whole anesthetic.
A single patient whose pain is genuine and whose drug clearance is genuinely unpredictable. The disagreement isn't about whether to treat neonatal pain — that debate is settled and everyone in the room knows it — it's about how far immature metabolism should actually move the dose down from there.